Drug Trial Radar · NCT05160922
Crizotinib Continuation Clinical Study
Last checked: Nov 20, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
27
Actual
Start
Dec 27, 2021
Primary completion
Mar 21, 2028
Study completion Mar 21, 2028
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Dec 16, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this continuation study is to provide continued access to crizotinib treatment for eligible participants from a current Pfizer sponsored crizotinib clinical study that is planned to close.
Conditions
- NSCLC
- ALCL
- IMT
Interventions
crizotinibDrug
crizotinib oral treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events leading to permanent discontinuation of study interventionTime frame: Baseline up to approximately 5 years
- Number of serious adverse events reported for all participantsTime frame: Baseline up to approximately 5 years
Locations
13 sites in 5 countries. Site status is shown where the registry gives one.
Shanghai Chest Hospital
Shanghai, China
Cancer Hospital Chinese Academy of Medical Science
Beijing, Beijing Municipality, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Fujian Province Oncology Hospital
Fuzhou, Fujian, China
Sun Yat-Sen University Cancer center
Guangzhou, Guangdong, China
The First Affiliated Hospital of Guangzhou Medical University.
Guangzhou, Guangzhou, China
Jilin Cancer Hospital
Changchun, Jilin, China
West China Hospital of Sichuan University
Wuhou District, Sichuan, China
The First Affiliated Hospital of College of Medicine,Zhejiang University
Hangzhou, Zhejiang, China
ASST Monza
Monza, MB, Italy
National Hospital Organization Nagoya Medical Center
Nagoya, Aichi-ken, Japan
Limited Liability Company "EuroCityClinic"
Saint Petersburg, Russia
National Taiwan University Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.